PUBLISHER: The Business Research Company | PRODUCT CODE: 1703204
PUBLISHER: The Business Research Company | PRODUCT CODE: 1703204
A congestive heart failure (CHF) treatment device is a medical tool created to assist in managing and addressing the effects of this condition, wherein the heart struggles to efficiently pump blood, resulting in fluid accumulation in the lungs and other tissues. Such devices play a role in monitoring, supporting, or enhancing heart function, thereby mitigating symptoms and reducing the likelihood of complications and hospitalizations associated with congestive heart failure.
The primary types of devices used in treating congestive heart failure encompass cardiac pacemakers, implantable cardioverter defibrillators (ICDs), cardiac resynchronization therapy (CRT) devices, counter-pulsation devices, and ventricular assist devices (VADs). A cardiac pacemaker, for example, is a small implant placed in the chest to regulate irregular heart rhythms by delivering electrical impulses to restore a normal heartbeat. These devices, including left ventricular assist devices (LVADs), right ventricular assist devices (RVADs), and biventricular assist devices (BIVADs), find utility across various settings, including hospitals, specialized cardiovascular treatment centers, and ambulatory surgery centers.
The congestive heart failure treatment devices market research report is one of a series of new reports from The Business Research Company that provides congestive heart failure treatment devices market statistics, including congestive heart failure treatment devices industry global market size, regional shares, competitors with a congestive heart failure treatment devices market share, detailed congestive heart failure treatment devices market segments, market trends and opportunities, and any further data you may need to thrive in the congestive heart failure treatment devices industry. This congestive heart failure treatment devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The congestive heart failure treatment devices market size has grown strongly in recent years. It will grow from $19.61 billion in 2024 to $21.21 billion in 2025 at a compound annual growth rate (CAGR) of 8.1%. The growth in the historic period can be attributed to the shift towards less invasive surgical techniques, the demand for minimally invasive structural heart devices, ongoing training and education programs for healthcare professionals, rising healthcare expenditure, and growing patient preference for non-surgical or minimally invasive treatment options.
The congestive heart failure treatment devices market size is expected to see strong growth in the next few years. It will grow to $28.64 billion in 2029 at a compound annual growth rate (CAGR) of 7.8%. The growth in the forecast period can be attributed to the increasing aging population, growing awareness about heart health, the implementation of screening programs, favorable reimbursement policies for structural heart procedures, and timely regulatory approvals for new structural heart devices. Major trends in the forecast period include increasing adoption of transcatheter valve replacement, ongoing development of innovative devices with advanced materials, growing emphasis on personalized treatment approaches, increasing adoption of hybrid procedures, and integration of remote monitoring and telehealth solutions.
The increasing prevalence of cardiovascular disorders is expected to drive the growth of the congestive heart failure (CHF) treatment devices market in the coming years. Cardiovascular disorders include a wide range of diseases that affect the heart and blood vessels, such as coronary artery disease, hypertension, and heart failure, all of which impact blood circulation and overall heart health. This rise in cardiovascular conditions is largely attributed to growing risk factors like obesity, sedentary lifestyles, poor dietary habits, and aging populations. Congestive heart failure treatment devices play a vital role in managing these disorders by regulating heart rhythms and improving heart function, thereby significantly enhancing patient outcomes. For example, a report by Charity Today, a UK-based charitable organization, stated in January 2024 that over 39,000 people in England died prematurely from cardiovascular conditions, including heart attacks, coronary heart disease, and stroke, in 2022. As a result, the increasing prevalence of cardiovascular diseases is fueling the growth of the CHF treatment devices market.
Leading companies in the congestive heart failure treatment devices market are focusing on developing innovative products, such as dual-chamber leadless pacemakers, to improve heart rhythm synchronization, minimize the risks associated with traditional pacemaker leads, enhance patient comfort, and provide more effective management of heart failure symptoms. These advancements aim to improve patients' quality of life and reduce hospital readmissions for those with arrhythmias. A dual-chamber leadless pacemaker is a cutting-edge device designed to regulate heart rhythms without the need for traditional leads (wires) typically implanted in the heart. For example, in February 2022, Abbott Laboratories, a US-based healthcare company, successfully implanted the world's first dual-chamber leadless pacemaker during a pivotal clinical trial. This groundbreaking device allows for heart rhythm management without the need for conventional leads, offering a less invasive procedure. The dual-chamber design facilitates simultaneous pacing of both the atrium and ventricle, improving the management of heart conditions. This innovation aims to provide patients with a more convenient and effective solution for heart rhythm disorders, potentially reducing hospital visits and enhancing overall quality of life. The device's performance is continuously monitored through advanced technologies, ensuring ongoing oversight of cardiac health.
In December 2022, Johnson & Johnson Services Inc., a pharmaceutical and medical technology company based in the United States, completed the acquisition of Abiomed Inc. for $16.6 billion. Through this strategic move, Johnson & Johnson aims to broaden its presence in the rapidly expanding cardiovascular device market, especially in the segments related to heart failure and recovery solutions. Abiomed Inc., headquartered in the United States, specializes in manufacturing devices for the treatment of congestive heart failure.
Major companies operating in the congestive heart failure treatment devices market are Abbott Laboratories, Medtronic plc, Baxter International Inc., Boston Scientific Corporation, Terumo Corporation, Edwards Lifesciences Corporation, Charles River Laboratories International Inc., W. L. Gore & Associates Inc., Bracco Group, LivaNova PLC, Meril Life Sciences Pvt. Ltd., Biotronik SE & Co. KG, CryoLife Inc., HeartWare International Inc., Direct Flow Medical Inc., Berlin Heart GmbH, CVRx Inc., Micro Interventional Devices Inc., Jarvik Heart Inc, CardioKinetix Inc, Xeltis AG, Ancora Heart Inc, ReliantHeart Inc.
North America was the largest region in the congestive heart failure treatment devices market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the congestive heart failure treatment devices market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the congestive heart failure treatment devices market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain
The congestive heart failure treatment device market consists of sales of external defibrillators, total artificial hearts (TAHs), implantable cardioverter defibrillators, and intra-aortic balloon pumps (IABPs). Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Congestive Heart Failure Treatment Devices Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on congestive heart failure treatment devices market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for congestive heart failure treatment devices ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The congestive heart failure treatment devices market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.